Comparative Pharmacology
Head-to-head clinical analysis: CANAGLIFLOZIN versus STEGLATRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANAGLIFLOZIN versus STEGLATRO.
CANAGLIFLOZIN vs STEGLATRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Steglatro (ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
100 mg orally once daily; may increase to 300 mg once daily for additional glycemic control.
0.5 mg orally once daily for patients with type 2 diabetes; no dose adjustment for age, gender, or race.
None Documented
None Documented
Terminal elimination half-life: 10.6–13.1 hours (single dose); steady-state: ~12.9 hours. Clinically, supports once-daily dosing with sustained SGLT2 inhibition over 24 hours.
Clinical Note
moderateCanagliflozin + Gatifloxacin
"Canagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateCanagliflozin + Rosoxacin
"Canagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateCanagliflozin + Levofloxacin
"Canagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateCanagliflozin + Trovafloxacin
"Canagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.4 hours in patients with type 2 diabetes, supporting once-daily dosing. No accumulation occurs at steady state.
Renal: 33% (primarily tubular secretion, ~1% unchanged in urine; remainder as glucuronide metabolites); Fecal: 52% (as parent drug and metabolites); Biliary: minor (enterohepatic circulation suspected but not quantified).
Approximately 65% of the dose is excreted in the urine as unchanged drug via active tubular secretion, and 35% is excreted in the feces as unchanged drug, indicating minimal metabolism.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor